| Mary Tran Mitsunaga, APRN | |
|
1301 Punchbowl St, Honolulu, HI 96813-2402 | |
| (808) 691-4427 | |
| Not Available |
| Full Name | Mary Tran Mitsunaga |
|---|---|
| Gender | Female |
| Speciality | Certified Clinical Nurse Specialist (cns) |
| Experience | 11 Years |
| Location | 1301 Punchbowl St, Honolulu, Hawaii |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245615236 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SG0600X | Clinical Nurse Specialist - Gerontology | 1751 (Hawaii) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Queens Medical Center | 3476454067 | 187 |
News Archive
AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).
Today the national science academies of the G7 countries handed three statements to their respective heads of government for discussion during the G7 summit at Schloss Elmau in early June 2015. The papers on antibiotic resistance, neglected and poverty-related diseases, and the future of the ocean were drawn up by the seven national academies under the aegis of the German National Academy of Sciences Leopoldina.
Medicare beneficiaries in some parts of the United States appear more likely to receive carotid endarterectomy, a surgical procedure to clear blockages in the artery supplying blood to the head, whereas those in other regions more often receive stents for the same condition, according to a report in the July 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
BioCryst Pharmaceuticals, Inc. announced that it has been awarded a $55.0 million contract modification by the U.S. Department of Health & Human Services intended to fund to completion the Phase 3 development of its neuraminidase inhibitor, intravenous peramivir, for the treatment of patients hospitalized with influenza.
› Verified 2 days ago
| Entity Name | The Queens Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487693586 PECOS PAC ID: 3476454067 Enrollment ID: O20040116000366 |
News Archive
AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).
Today the national science academies of the G7 countries handed three statements to their respective heads of government for discussion during the G7 summit at Schloss Elmau in early June 2015. The papers on antibiotic resistance, neglected and poverty-related diseases, and the future of the ocean were drawn up by the seven national academies under the aegis of the German National Academy of Sciences Leopoldina.
Medicare beneficiaries in some parts of the United States appear more likely to receive carotid endarterectomy, a surgical procedure to clear blockages in the artery supplying blood to the head, whereas those in other regions more often receive stents for the same condition, according to a report in the July 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
BioCryst Pharmaceuticals, Inc. announced that it has been awarded a $55.0 million contract modification by the U.S. Department of Health & Human Services intended to fund to completion the Phase 3 development of its neuraminidase inhibitor, intravenous peramivir, for the treatment of patients hospitalized with influenza.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mary Tran Mitsunaga, APRN 1301 Punchbowl St, Honolulu, HI 96813-2402 Ph: (808) 691-4427 | Mary Tran Mitsunaga, APRN 1301 Punchbowl St, Honolulu, HI 96813-2402 Ph: (808) 691-4427 |
News Archive
AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).
Today the national science academies of the G7 countries handed three statements to their respective heads of government for discussion during the G7 summit at Schloss Elmau in early June 2015. The papers on antibiotic resistance, neglected and poverty-related diseases, and the future of the ocean were drawn up by the seven national academies under the aegis of the German National Academy of Sciences Leopoldina.
Medicare beneficiaries in some parts of the United States appear more likely to receive carotid endarterectomy, a surgical procedure to clear blockages in the artery supplying blood to the head, whereas those in other regions more often receive stents for the same condition, according to a report in the July 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
BioCryst Pharmaceuticals, Inc. announced that it has been awarded a $55.0 million contract modification by the U.S. Department of Health & Human Services intended to fund to completion the Phase 3 development of its neuraminidase inhibitor, intravenous peramivir, for the treatment of patients hospitalized with influenza.
› Verified 2 days ago
Ms. Christine Piper, R.N. Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: Tripler Army Medical Center, Honolulu, HI 96859 Phone: 808-433-8600 | |
Brenda M. Hiromoto, CNS Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 3288 Moanalua Rd, Honolulu, HI 96819 Phone: 808-432-0000 | |
Ms. Shanyn Kimie Patterson, APRN, CNS Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 459 Patterson Rd, Honolulu, HI 96819 Phone: 808-433-0062 | |
Mrs. Lianne Sadako Higa, APRN-CNS Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 550 S Beretania St Ste 601, Honolulu, HI 96813 Phone: 808-619-7771 Fax: 808-691-7770 | |
Mrs. Lynn Natsuko Muneno, MS, RN, ACNS-BC Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 1301 Punchbowl St, Honolulu, HI 96813 Phone: 808-691-5348 Fax: 808-691-7822 | |
Mr. Norman Howard Reeves Ii, APRN-CCNS Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 500 Ala Moana Blvd, Suite 200, Honolulu, HI 96813 Phone: 808-522-7500 | |
Mr. Jeffrey Viernes, APRN Clinical Nurse Specialist Medicare: Medicare Enrolled Practice Location: 550 S Beretania St Ste 601, Honolulu, HI 96813 Phone: 808-691-7770 Fax: 808-691-7771 |